Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Medicare covers weight loss drugs including Ozempic under specific conditions when the drug also has potential use cases beyond weight loss.

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

WEIGHT loss drugs are still being brazenly flogged on the black market by a celebrity hairdresser who gave The Sun a Mounjaro ...

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach? Medical experts weigh in.

WEIGHT loss jabs are weaving themselves into the fabric of our daily lives and chances are you know someone taking them – or ...